Last updated: February 25, 2026
What is NDC 00065-4147?
NDC 00065-4147 refers to Remdesivir (Veklury), an antiviral drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19. It is manufactured by Gilead Sciences.
Current Market Landscape
Sales Data and Adoption
- COVID-19 treatments market, including remdesivir, peaked during 2020-2021, primarily driven by the pandemic.
- Gilead's remdesivir generated approximately $2.5 billion in 2021, with initial sales high during early pandemic waves.
- Sales declined in 2022 as alternative treatments emerged and vaccination rates increased.
- Volume estimates suggest the drug is administered mainly in hospital settings, with annual U.S. sales approximately $1.2 billion in 2022.
Competitive Landscape
- Key competitors: Paxlovid (Pfizer), Molnupiravir (Merck).
- Paxlovid and Molnupiravir are oral antivirals, offering ease of use over IV-administered remdesivir.
- Market share shifted toward oral treatments due to convenience and administration setting.
Regulatory and Reimbursement Status
- Gilead has obtained post-approval pricing agreements with federal health programs.
- Price in the U.S. has been set at approximately $520 per 100 mg vial, with treatment courses requiring six vials (~$3,120 per course).
- Federal procurement contracts have historically influenced pricing and availability.
Price Projections
Short-term (Next 12-24 Months)
- Prices are likely to stabilize around current levels due to limited new competition.
- Pandemic-related emergency use authorizations (EUAs) may influence procurement volumes but not significantly alter pricing for hospital-administered treatments.
- Entry of oral antivirals reduces demand. Gilead might consider pricing adjustments to maintain market share or expand indications.
Long-term (Next 3-5 Years)
- As COVID-19 transitions to endemic status, demand may decline.
- Gilead could seek regulatory approval for remdesivir in other indications (e.g., Ebola, hepatitis C).
- Price projections for remdesivir are expected to decrease by 20-30% over five years due to market saturation, generic competition if patent protections expire, and reduced COVID-19 cases.
- If Gilead extends patent protection or introduces new formulations, the price may sustain or slightly increase temporarily.
Factors Influencing Price Change
| Factor |
Impact |
Notes |
| Patent expiration |
Decrease |
Generic competition expected post-2025 |
| New indications |
Price increase |
Potential approval for other viral diseases |
| Pandemic evolution |
Demand decline |
Reduced COVID-19 case numbers |
Key Market Dynamics
- Regulatory approval for new uses could sustain or increase future sales.
- Pricing strategies will depend on payer negotiations and public health policies.
- Market share may diminish if oral antivirals dominate outpatient setting treatments.
- Supply chain stability remains critical amid COVID-19 variability, influencing pricing.
Summary
- Currently, remdesivir (NDC 00065-4147) generates over $1 billion annually in the U.S.
- Short-term pricing remains stable at about $520 per vial.
- Over the next five years, prices are likely to decline 20-30%, driven by emerging oral therapies and market maturity.
- Long-term, patent expiry and new indications could alter price trends, either positively or negatively.
Key Takeaways
- Remdesivir remains active in hospitals primarily for COVID-19 treatment.
- Market share is decreasing in favor of oral antivirals.
- Prices are stable but face downward pressure amid evolving treatment protocols.
- Future sales depend on regulatory approvals, viral evolution, and potential new indications.
FAQs
1. What factors influence remdesivir’s price stability?
Pricing is mainly influenced by market demand, competition from oral antivirals, reimbursement agreements, and procurement policies. Patent status also affects potential generic entry and price reductions.
2. How will emerging COVID-19 treatments impact remdesivir sales?
Oral treatments like Paxlovid and Molnupiravir offer convenience and are often preferred in outpatient settings, reducing demand for IV-administered remdesivir, which may result in declining sales and prices.
3. When can we expect patent expiration for remdesivir?
Gilead Sciences filed patents extending into the late 2020s; patent expiration could occur around 2025-2027, allowing for generic competition.
4. Are there opportunities for remdesivir in indications beyond COVID-19?
Yes, remdesivir has potential uses for other viral diseases such as Ebola and hepatitis C, which could influence future pricing and sales if approved.
5. How does government procurement affect remdesivir’s market prices?
Government contracts can set fixed procurement prices, which might keep prices stable in the short term but may also pressure Gilead to lower prices in the future to secure volume.
References
[1] Gilead Sciences. (2022). Remdesivir (Veklury) official drug label. U.S. FDA.
[2] IQVIA. (2022). U.S. COVID-19 treatment market report.
[3] Statista. (2022). COVID-19 antiviral drug sales and market shares.
[4] FDA. (2020). Emergency use authorization for remdesivir.
[5] Congressional Budget Office. (2022). Drug patent expiration timelines.
